Isocitrate dehydrogenase (IDH)–mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 ...
Vorasidenib becomes the first targeted therapy for grade 2 isocitrate dehydrogenase (IDH)–mutant glioma to receive FDA approval. "Today's approval of Voranigo is an enormous leap forward in cancer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results